Allen Redding, MD
Endocrinology, Diabetes & Metabolism · Little Rock, ARNPI 1538197256
Payments from drug & device makers
Across 388 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$605
- Dexcom, Inc.$605
- Bayer$563
- Amgen$532
- AbbVie$519
- Corcept Therapeutics$365
- plus $3K from 33 others
What the payments were for
- Food & beverage$6,62199%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 40 | $605 |
| Dexcom, Inc. | 52 | $605 |
| Bayer | 36 | $563 |
| Amgen | 46 | $532 |
| AbbVie | 23 | $519 |
| Corcept Therapeutics | 20 | $365 |
| Xeris Pharmaceuticals, Inc. | 16 | $364 |
| Abbott | 20 | $363 |
| Novo Nordisk | 20 | $306 |
| Sanofi-aventis U.S. LLC | 14 | $246 |
| Cequr Corporation | 2 | $226 |
| Mannkind Corporation | 8 | $162 |
| Boehringer Ingelheim | 10 | $159 |
| Novartis | 9 | $149 |
| Insulet Corporation | 5 | $148 |
| Radius Health, Inc. | 5 | $114 |
| Kyowa Kirin, Inc. | 4 | $106 |
| Ascendis Pharma Endocrinology Inc | 5 | $99 |
| Neurocrine Biosciences, Inc. | 4 | $97 |
| Recordati_rare_diseases_inc. | 5 | $96 |
| Antares Pharma, Inc. | 4 | $77 |
| Regeneron Healthcare Solutions, Inc. | 4 | $73 |
| Almatica Pharma LLC | 4 | $73 |
| Tandem Diabetes Care, Inc. | 4 | $69 |
| AstraZeneca | 4 | $66 |
| BETA Bionics, Inc. | 4 | $66 |
| Chiesi USA, Inc. | 3 | $61 |
| Nevro Corp. | 4 | $58 |
| Averitas Pharma Inc. | 2 | $54 |
| Boston Scientific | 1 | $41 |
| Sequel Med Tech, LLC | 2 | $37 |
| Medtronic | 1 | $23 |
| Merck | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Rhythm Pharmaceuticals, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $20 |
| Soleno Therapeutics, Inc. | 1 | $19 |
| Globus Medical | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$149
- Synthroid$105
How this compares
$6,655 in reported general payments places this provider in the 45th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 519 | $585,191 |
| MounjaroTirzepatide | 277 | $370,831 |
| JardianceEmpagliflozin | 373 | $315,202 |
| Tresiba Flextouch U-200Insulin Degludec | 161 | $257,799 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 143 | $256,295 |
| TrulicityDulaglutide | 150 | $185,853 |
| Tresiba Flextouch U-100Insulin Degludec | 232 | $172,694 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 184 | $126,851 |
| FarxigaDapagliflozin Propanediol | 90 | $97,437 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 82 | $86,889 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 78 | $83,990 |
| Humalog Kwikpen U-200Insulin Lispro | 38 | $80,510 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 85 | $56,654 |
| Novolog FlexpenInsulin Aspart | 158 | $51,815 |
| Humalog Kwikpen U-100Insulin Lispro | 130 | $49,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro | $605 | $623,406547 claims |
| Novo NordiskOzempic, Rybelsus, Levemir, Novolog | $306 | $622,420582 claims |
| Boehringer IngelheimJardiance | $159 | $315,202373 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $246 | $98,758151 claims |
| AstraZenecaFarxiga | $66 | $97,43790 claims |
| AbbVieSynthroid | $519 | $25,081329 claims |
| MerckJanuvia, Janumet Xr | $23 | $16,19924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Little Rock
- James ThrasherLittle Rock$4M
- Richard GriffithsLittle Rock$925K
- Madhu BudhrajaLittle Rock$461K
- Irina LendelLittle Rock$87K
- Donald BodennerLittle Rock$51K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
- Teresa NimmoLittle Rock$29K
- Joseph HenskeLittle Rock$23K
- Nidhi JainLittle Rock$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.